PT Indofarma Tbk

IDX:INAF Stock Report

Market Cap: Rp390.5b

Indofarma Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

. Yeliandriani

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenure1.2yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

CEO

. Yeliandriani (60 yo)

less than a year

Tenure

Yeliandriani is President Director of PT Indofarma Tbk from January 11, 2024. Yeliandriani has a Bachelor of Accounting from Sekolah Tinggi Ilmu Ekonomi Swadaya, Associate Degree in Accounting from Polytec...

Leadership Team

NamePositionTenureCompensationOwnership
. Yeliandriani
President Directorless than a yearno datano data
Andi Prazos
Director of Operations & Directorless than a yearno datano data
Sigit Prakosa
Head of Internal Audit Unit3.1yrsno datano data
Warjoko Sumedi
Corporate Secretary1.2yrsno datano data
Weny Maulatsih
Secretary of Board of Commissioners7.3yrsRp129.01mno data

1.2yrs

Average Tenure

53yo

Average Age

Experienced Management: INAF's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
. Yeliandriani
President Directorless than a yearno datano data
Andi Prazos
Director of Operations & Directorless than a yearno datano data
Teddy Wibisana
Independent Commissioner9.7yrsRp856.58mno data
Didi Mintadi
Commissioner4.2yrsRp856.58mno data
Laksono Trisnantoro
President Commissioner3.3yrsRp491.40mno data

3.3yrs

Average Tenure

60yo

Average Age

Experienced Board: INAF's board of directors are considered experienced (3.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/09/28 05:34
End of Day Share Price 2024/07/01 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PT Indofarma Tbk is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yohan SetioPT Mandiri Sekuritas
Guntur HariyantoPT PEFINDO